Short answers here; every one links out to a deep file — the journal, medication references, glossary, and ledger — where the citations live. Educational only, not medical advice.
About this site
How does this site make money?
Through disclosed affiliate relationships — principally a material connection between our operator, Sam LLC, and NexLife. That connection is stated on every commercial page, and it is why our core rule exists: no price, score, or claim is published for any provider, including NexLife, until a human verifies it against the provider’s own checkout and terms on a stated date.
Why do you only show one provider’s prices?
Because only one has completed verification. Ten competitors sit in a public queue with every field marked “pending verification” rather than filled with numbers copied from their ads. We think an honest empty cell beats a confident wrong one; queue order and standards are on the methodology page.
Isn’t recommending a partner a conflict of interest?
It’s a managed one: disclosure on every page, identical rubric applied to everyone, published verification dates, a corrections channel, and pending-status honesty for the rest of the market. Judge us by whether the ledger fills in fairly — and tell us when it doesn’t.
Is anything here medical advice?
No. Every page is educational. Medical review of our content is pending a named clinician (the slot is open on the editorial-policy page), and dosing decisions belong with your prescriber.
The medications
What’s the difference between tirzepatide and semaglutide?
Tirzepatide activates two receptors (GIP + GLP-1) and averaged 20.2% weight loss against semaglutide’s 13.7% in their head-to-head trial. Semaglutide counters with the class’s only proven cardiovascular-event reduction in people without diabetes (SELECT). Averages aren’t individuals — the full comparison is in the journal.
Are tirzepatide tablets real?
No FDA-approved oral tirzepatide exists in any form. Compounded ODTs and drops are sold without published outcome trials; our analysis explains why oral peptide delivery is genuinely hard and what Rybelsus had to engineer to manage it for semaglutide.
Do I regain weight after stopping?
On average, yes — substantially. In SURMOUNT-4, stopping tirzepatide reversed much of the loss within a year while continuing preserved it. Planning for maintenance — tapering, budget, or both — belongs in the decision from day one.
What are the most common side effects?
Gastrointestinal, concentrated during dose escalation: nausea (roughly 44% in semaglutide’s STEP 1; mid-20s% in tirzepatide trials), constipation, diarrhea, vomiting. Most cases are mild-to-moderate and manageable; the side-effects and nausea-management files cover base rates and protocols.
What does the thyroid boxed warning actually mean?
Rodents given these drugs developed thyroid C-cell tumors; whether that translates to humans is unknown, and human studies are conflicting. The hard rule: personal or family history of medullary thyroid carcinoma or MEN 2 means don’t use the class. Routine calcitonin screening isn’t recommended.
Who shouldn’t take a GLP-1 at all?
Beyond the MTC/MEN 2 contraindication: pregnancy (and planning — semaglutide needs a two-month washout), history of pancreatitis warrants caution, severe gastroparesis, and prior serious hypersensitivity. This list isn’t exhaustive — screening is what the prescriber visit is for.
Does the birth-control interaction apply to both drugs?
No — it’s tirzepatide-specific. Its label says oral hormonal contraceptives may be less effective around initiation and dose increases: use a barrier or non-oral method for four weeks after each. Semaglutide’s studies found no such effect.
Is microdosing legitimate?
It’s a marketing category, not an evidence category. Below-label doses cost less and cause fewer side effects, but every published efficacy number comes from labeled doses. Our evidence file separates what’s known from what’s extrapolated.
Can I drink alcohol on a GLP-1?
No absolute prohibition exists, but many users report sharply reduced desire and faster effects; hypoglycemia risk rises when combined with diabetes medications, and both irritate the stomach. The alcohol-cravings file covers the emerging science.
What about surgery and anesthesia?
Tell every surgical and anesthesia team you’re on a GLP-1 — slowed stomach emptying raises aspiration concerns, and guidance on holding doses has evolved. Our surgery guide walks the current recommendations.
Buying and pricing
What’s the cheapest verified GLP-1 program right now?
As of our dated verification: flat-rate compounded semaglutide at $119–139/month and tirzepatide at $139–169/month (NexLife — disclosed connection), with microdose plans lower. Ten competitors are queued and could beat those figures once verified; insurance copays beat everything when coverage exists.
Why do advertised prices differ from what I’d pay?
Teaser structure: a first-month or lowest-dose price headlines the ad while maintenance doses, membership fees, and “provider fees” inflate the real total — sometimes several-fold across a year. Our teaser-pricing anatomy dissects a real example; the calculator computes any program’s true 12-month cost.
Is compounded GLP-1 legal in 2026?
Contested. Mass compounding’s clear legal basis ended with the FDA shortage resolutions; what remains runs on narrower rationales — patient-specific “personalization” chief among them — that regulators and manufacturers are actively fighting. The legal-status file maps lanes, litigation, and what a buyer should verify.
Compounded vs brand — how do I think about it?
Brand product carries FDA approval, manufacturing oversight, and the actual trial evidence; compounded product carries a lower price and a contested legal lane. Manufacturer self-pay channels (LillyDirect, NovoCare) sit between. Our switching guide covers dose mapping if you move between them.
Will insurance cover my prescription?
Diabetes indications: often. Weight-management indications: inconsistently, with prior authorization the norm and outright exclusions common. The newer cardiovascular, sleep-apnea, and kidney indications unlock coverage weight alone can’t — including some Medicare pathways. The coverage file has the tactics.
How do I verify an online pharmacy is legitimate?
Require a real prescription, look up the pharmacy’s state license, check LegitScript/NABP status, confirm a physical U.S. address and reachable pharmacist, and treat crypto-only payment or “research use” language as disqualifying. Our checklist article walks all eight steps.
Are “research peptides” a cheaper way in?
They’re the most dangerous corner of this market: unregulated vials of unverified identity and sterility, sold with no prescriber and no recourse. Every pipeline name (retatrutide especially) is counterfeited this way. The gray-market file is our longest warning for a reason.
Can I buy retatrutide or orforglipron anywhere?
No. Neither is approved; neither has ever left legitimate trial supply chains. Anything sold under those names is counterfeit by definition.
Practical use
What if I miss a dose?
Labels allow a late weekly dose within 4 days (tirzepatide) or 5 days (Ozempic); past the window, skip and resume schedule — never double. Daily liraglutide simply resumes next day. Longer gaps may mean re-titrating; that’s a prescriber call.
How do I store and travel with these medications?
Refrigerate until first use, never freeze, and learn your product’s in-use room-temperature window — they differ by product (e.g., 21 days for tirzepatide pens, 56 for Ozempic; check your label). Fly with medication in carry-on, never checked baggage. The travel guide has the full kit list.
How fast will I lose weight?
Trial averages: meaningful loss by 12–16 weeks, continuing past a year, with enormous individual spread — including 10–15% of participants who respond minimally. Early weeks on starter doses are tolerability phases, not verdicts. The plateau file covers what stalls mean.
How do I protect muscle while losing?
Protein at roughly 1.2–1.6 g/kg/day and resistance training two-plus times weekly — the two interventions with real evidence. Rapid loss without them costs disproportionate lean mass, which matters more with age. The muscle file has the playbook.
Do I have to stay on it forever?
The honest framing: obesity behaves like a chronic condition, and the trials show regain when treatment stops. Some people taper to maintenance strategies successfully; the taper file covers what’s known about doing it deliberately rather than abruptly.
Something we didn’t answer?
Ask via corrections; genuinely common questions get added with their own sourced answer.